CytoDyn Inc. (CYDY)
USD 0.23
(-1.61%)
USD 0.23
(-1.61%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 127.89 Million USD | 5.88% |
| 2023 | 120.79 Million USD | -2.26% |
| 2022 | 123.58 Million USD | -19.28% |
| 2021 | 153.09 Million USD | 188.89% |
| 2020 | 52.99 Million USD | 77.9% |
| 2019 | 29.78 Million USD | 64.97% |
| 2018 | 18.05 Million USD | 97.16% |
| 2017 | 9.15 Million USD | 155.78% |
| 2016 | 3.58 Million USD | -76.71% |
| 2015 | 15.37 Million USD | 241.21% |
| 2014 | 4.5 Million USD | 2.82% |
| 2013 | 4.38 Million USD | -13.14% |
| 2012 | 5.04 Million USD | -27.96% |
| 2011 | 7 Million USD | 1047.62% |
| 2010 | 610.16 Thousand USD | -39.29% |
| 2009 | 1 Million USD | -33.06% |
| 2008 | 1.5 Million USD | 26.32% |
| 2007 | 1.18 Million USD | 60.21% |
| 2006 | 741.8 Thousand USD | -8.1% |
| 2005 | 807.15 Thousand USD | 289.91% |
| 2004 | 207.01 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 FY | 127.89 Million USD | 5.88% |
| 2024 Q1 | 129.3 Million USD | 7.04% |
| 2024 Q2 | 123.62 Million USD | -4.39% |
| 2024 Q3 | 129.65 Million USD | 4.88% |
| 2024 Q4 | 127.89 Million USD | -1.36% |
| 2023 Q4 | 120.79 Million USD | -0.71% |
| 2023 Q3 | 121.65 Million USD | -1.13% |
| 2023 Q1 | 122.7 Million USD | -0.71% |
| 2023 FY | 120.79 Million USD | -2.26% |
| 2023 Q2 | 123.04 Million USD | 0.27% |
| 2022 Q2 | 116.39 Million USD | -10.58% |
| 2022 FY | 123.58 Million USD | -19.28% |
| 2022 Q1 | 130.16 Million USD | -14.98% |
| 2022 Q4 | 123.58 Million USD | 6.04% |
| 2022 Q3 | 116.53 Million USD | 0.12% |
| 2021 FY | 153.09 Million USD | 188.89% |
| 2021 Q3 | 129.44 Million USD | -13.87% |
| 2021 Q2 | 150.29 Million USD | 65.9% |
| 2021 Q1 | 90.59 Million USD | 70.95% |
| 2021 Q4 | 153.09 Million USD | 18.27% |
| 2020 Q2 | 31.54 Million USD | 25.29% |
| 2020 Q4 | 52.99 Million USD | 22.67% |
| 2020 FY | 52.99 Million USD | 77.9% |
| 2020 Q1 | 25.18 Million USD | -15.47% |
| 2020 Q3 | 43.2 Million USD | 36.94% |
| 2019 Q3 | 26.67 Million USD | -6.25% |
| 2019 FY | 29.78 Million USD | 64.97% |
| 2019 Q4 | 29.78 Million USD | 11.66% |
| 2019 Q1 | 28.82 Million USD | 59.65% |
| 2019 Q2 | 28.45 Million USD | -1.3% |
| 2018 Q2 | 19.28 Million USD | 33.11% |
| 2018 FY | 18.05 Million USD | 97.16% |
| 2018 Q4 | 18.05 Million USD | 13.73% |
| 2018 Q3 | 15.87 Million USD | -17.65% |
| 2018 Q1 | 14.48 Million USD | 58.16% |
| 2017 FY | 9.15 Million USD | 155.78% |
| 2017 Q4 | 9.15 Million USD | -1.95% |
| 2017 Q3 | 9.34 Million USD | -9.29% |
| 2017 Q2 | 10.29 Million USD | 238.78% |
| 2017 Q1 | 3.03 Million USD | -15.12% |
| 2016 FY | 3.58 Million USD | -76.71% |
| 2016 Q4 | 3.58 Million USD | 5.96% |
| 2016 Q3 | 3.37 Million USD | -63.55% |
| 2016 Q2 | 9.27 Million USD | -27.88% |
| 2016 Q1 | 12.85 Million USD | -16.39% |
| 2015 Q4 | 15.37 Million USD | 83.58% |
| 2015 FY | 15.37 Million USD | 241.21% |
| 2015 Q1 | 4.9 Million USD | 8.89% |
| 2015 Q2 | 7.35 Million USD | 49.87% |
| 2015 Q3 | 8.37 Million USD | 13.89% |
| 2014 FY | 4.5 Million USD | 2.82% |
| 2014 Q2 | 4.15 Million USD | -14.7% |
| 2014 Q4 | 4.5 Million USD | 5.98% |
| 2014 Q1 | 4.86 Million USD | 11.08% |
| 2014 Q3 | 4.25 Million USD | 2.39% |
| 2013 Q1 | 5.66 Million USD | 12.22% |
| 2013 FY | 4.38 Million USD | -13.14% |
| 2013 Q4 | 4.38 Million USD | -4.89% |
| 2013 Q3 | 4.6 Million USD | -13.8% |
| 2013 Q2 | 5.34 Million USD | -5.58% |
| 2012 FY | 5.04 Million USD | -27.96% |
| 2012 Q2 | 7.33 Million USD | -0.87% |
| 2012 Q3 | 5.01 Million USD | -31.68% |
| 2012 Q4 | 5.04 Million USD | 0.66% |
| 2012 Q1 | 7.4 Million USD | 5.68% |
| 2011 Q3 | 7.84 Million USD | 1676.47% |
| 2011 Q4 | 7 Million USD | -10.72% |
| 2011 Q1 | 362.99 Thousand USD | -40.51% |
| 2011 FY | 7 Million USD | 1047.62% |
| 2011 Q2 | 441.5 Thousand USD | 21.63% |
| 2010 Q1 | 783.69 Thousand USD | -22.02% |
| 2010 Q4 | 610.16 Thousand USD | -24.78% |
| 2010 FY | 610.16 Thousand USD | -39.29% |
| 2010 Q2 | 872.43 Thousand USD | 11.32% |
| 2010 Q3 | 811.13 Thousand USD | -7.03% |
| 2009 Q2 | 1.44 Million USD | -1.16% |
| 2009 Q1 | 1.46 Million USD | -2.74% |
| 2009 FY | 1 Million USD | -33.06% |
| 2009 Q4 | 1 Million USD | -27.5% |
| 2009 Q3 | 1.38 Million USD | -3.94% |
| 2008 Q1 | 1.34 Million USD | 13.0% |
| 2008 Q4 | 1.5 Million USD | 8.03% |
| 2008 Q3 | 1.38 Million USD | -1.86% |
| 2008 Q2 | 1.41 Million USD | 5.44% |
| 2008 FY | 1.5 Million USD | 26.32% |
| 2007 Q1 | 862.8 Thousand USD | 16.31% |
| 2007 Q3 | 892.79 Thousand USD | 8.2% |
| 2007 Q4 | 1.18 Million USD | 33.12% |
| 2007 FY | 1.18 Million USD | 60.21% |
| 2007 Q2 | 825.12 Thousand USD | -4.37% |
| 2006 Q4 | 741.8 Thousand USD | 5.94% |
| 2006 Q1 | 650.04 Thousand USD | -19.46% |
| 2006 Q2 | 630.28 Thousand USD | -3.04% |
| 2006 Q3 | 700.19 Thousand USD | 11.09% |
| 2006 FY | 741.8 Thousand USD | -8.1% |
| 2005 Q2 | 252.69 Thousand USD | 18.58% |
| 2005 FY | 807.15 Thousand USD | 289.91% |
| 2005 Q3 | 769.66 Thousand USD | 204.59% |
| 2005 Q1 | 213.1 Thousand USD | 2.94% |
| 2005 Q4 | 807.15 Thousand USD | 4.87% |
| 2004 Q2 | 106.69 Thousand USD | 0.0% |
| 2004 Q3 | 165.57 Thousand USD | 55.19% |
| 2004 FY | 207.01 Thousand USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q4 | 207.01 Thousand USD | 25.03% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -466104.936% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -1251.099% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -76.476% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -15712.926% |
| Rebus Holdings, Inc. | 5.24 Million USD | -2339.794% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -116.718% |
| Qrons Inc. | 1.48 Million USD | -8490.91% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -10329.999% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -70.707% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -286041.937% |
| Skye Bioscience, Inc. | 14.07 Million USD | -808.84% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -139.929% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -1234.729% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -30237.692% |
| SQZ Biotechnologies Company | 50.03 Million USD | -155.589% |
| Intellipharmaceutics International Inc. | 12 Million USD | -965.005% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -3220.694% |
| Mesoblast Limited | 188.44 Million USD | 32.132% |
| Marizyme, Inc. | 26.67 Million USD | -379.44% |
| Genus plc | 485 Million USD | 73.63% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -2088.983% |
| Pharming Group N.V. | 244.07 Million USD | 47.6% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -6262.474% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -4982.565% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -3265.632% |
| ContraFect Corporation | 32.53 Million USD | -293.145% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -6355.029% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -3241.321% |
| IMV Inc. | 37.93 Million USD | -237.159% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -985.854% |
| MultiCell Technologies, Inc. | 1617.67 USD | -7905962.423% |
| ONE Bio Corp. | 27.49 Million USD | -365.14% |
| Accustem Sciences Inc. | 1.07 Million USD | -11750.387% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -65.201% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -5946.8% |
| Q BioMed Inc. | 8.13 Million USD | -1472.543% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -54.21% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -2385.292% |
| Biomind Labs Inc. | 1.49 Million USD | -8434.164% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -7.725% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -1314.413% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -594.947% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -8819.554% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -89905.982% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -63492.156% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -2125.861% |
| GB Sciences, Inc. | 5.41 Million USD | -2260.732% |
| Alpha Cognition Inc. | 7.16 Million USD | -1685.039% |
| HST Global, Inc. | 593.59 Thousand USD | -21445.739% |
| CSL Limited | 18.62 Billion USD | 99.313% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -10056.823% |
| Halberd Corporation | 728.71 Thousand USD | -17450.524% |
| Enzolytics Inc. | 365.26 Million USD | 64.986% |
| Agentix Corp. | 2.51 Million USD | -4994.252% |
| Resverlogix Corp. | 67.39 Million USD | -89.765% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -15148.494% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 71.257% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -7361.727% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -416.826% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -974.46% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -3389.448% |
| AVAX Technologies, Inc. | 3.99 Million USD | -3102.358% |
| Zenith Capital Corp. | 27.56 Thousand USD | -463805.111% |
| Genscript Biotech Corporation | 1.32 Billion USD | 90.354% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -53489.716% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -3324.84% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -18684.902% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -4616.48% |
| Kadimastem Ltd | 3.5 Million USD | -3549.04% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -190989.065% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -154.445% |
| BioStem Technologies, Inc. | 15.9 Million USD | -704.129% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -27421.901% |
| LadRx Corporation | 2.2 Million USD | -5711.969% |
| Cell Source, Inc. | 15.8 Million USD | -709.112% |
| Regen BioPharma, Inc. | 5.45 Million USD | -2243.404% |
| Regen BioPharma, Inc. | 5.45 Million USD | -2243.404% |
| NovAccess Global Inc. | 7.86 Million USD | -1526.999% |
| Affymax, Inc. | 8.87 Million USD | -1341.709% |
| Itoco Inc. | 1.65 Million USD | -7636.377% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -6133.973% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -2014.3% |
| Mobile Lads Corp. | 1.31 Million USD | -9636.908% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -305873.827% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -8064.956% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -1057.905% |
| SYBLEU INC | 681.41 Thousand USD | -18668.94% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -1995.968% |
| International Stem Cell Corporation | 5.27 Million USD | -2323.612% |
| Bioxytran, Inc. | 3.24 Million USD | -3835.806% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -20336.587% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -2669.992% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -211.967% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -474.417% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -6214.546% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -2234.684% |
| Neutra Corp. | 973.52 Thousand USD | -13037.154% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -340.786% |
| PureTech Health plc | 125.58 Million USD | -1.84% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -3304.039% |
| IXICO plc | 1.9 Million USD | -6630.229% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -522.992% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -23.78% |
| CSL Limited | 18.62 Billion USD | 99.313% |
| Cellectis S.A. | 249.36 Million USD | 48.713% |